Abstract
Enzyme kinetic studies of lysoPAF acetyltransferase from microsomal preparations of human and rat neutrophils were carried out using lysoPAF or dansyllysoPAF as substrate. With the human enzyme, incomplete conversion of the substrate into the product was observed at 37°C with both substrates. The acetyltransferase was inactivated at 37°C in the absence of substrate with a half-life of 7.5 min. However, the initial rate of product formation under the assay conditions was linear up to 10 min. Both enzymes were optimally active at 40 μM concentration with either substrate, but enzyme activity was inhibited at higher substrate levels. At a constant substrate concentration (40 μM), the Km (μM) and Vmax (nmol product/min/mg protein) values for the human acetyltransferase, with respect to acetyl-CoA were 132 and 23.1, respectively, with lysoPAF as substrate, and 105 and 26.7, respectively, when dansyllysoPAF was used. The Km and Vmax values for the rat enzyme were 105 and 6.5, respectively, with lysoPAF as substrate, and 120 and 5.4, respectively, when dansyllysoPAF was used. Under our standard conditions, lysoPAF required 1 mg of BSA per mL in the assay, whereas full activity of both enzymes was seen with dansyllysoPAF even in the absence of BSA. The results show that dansyllysoPAF can replace lysoPAF in the assay without any significant changes in kinetic parameters.
Similar content being viewed by others
Abbreviations
- BSA:
-
bovine serum albumin
- dansyllysoPAF:
-
1-(N-dansyl-11-amino-1-undecyl)-GPC
- dansylPAF:
-
1-(N-dansyl-11-amino-1-undecyl)-2-acetyl-GPC
- EDTA:
-
ethylene diamine tetraacetic acid
- GPC:
-
sn-glycero-3-phosphocholine
- HBSS:
-
Hank's balanced salt solution
- lysoPAF:
-
1-O-alkyl-GPC
- PAF:
-
platelet-activating factor, Pafacether, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine
- PMN:
-
polymorphonuclear leukocytes
- PMSF:
-
phenylmethylsulfonyl fluoride
- TLC:
-
thin-layer chromatography
References
Doebber, T.W., Wu, M.S., Robbins, J.C., Choy, B.M., Chang, M.N., and Shen, T.Y. (1985)Biochem. Biophys. Res. Commun. 127, 799–808.
Venuti, M.C. (1985)Ann. Rep. Med. Chem. 20, 193–202.
Morley, J. (1986)Agents Actions 19, 100–108.
Bourgain, R.H., Maes, L., Braquet, P., Andries, R., Touqui, R., and Braquet, M. (1985)Prostaglandins 30, 185–197.
Snyder, F. (ed.) (1985) inMedicinal Research Reviews, Vol. 5, pp. 107–140, John Wiley and Sons Ltd., Winchester.
Ninio, E. (1987) inNew Horizons in Platelet-Activating Factor Research (Winslow, C.M., and Lee, M., eds.) pp. 27–35, John Wiley and Sons Ltd., mWinchester.
Robbins, J.C., Machoy, B.H., Lam, M.H., Ponpipom, M.M., Rupprecht, K.M., and Shen, T.Y. (1985)Fed. Proc. 44, 1269.
Billah, M.M., and Siegel, M.I. (1984)Biochem. Biophys. Res. Commun. 118, 629–635.
Billah, M.M., Briant, R.W., and Siegel, M.I. (1985)J. Biol. Chem. 260, 6899–6906.
Joly, F., Bessou, G., Benveniste, J., and Ninio, E. (1987)Eur. J. Pharmacol. 144, 133–139.
Schindler, P.W., Walter, R., and Hendrickson, H.S. (1988)Anal. Biochem. 174, 477–484.
Ninio, E., Mencia-Huerta, J.M., and Benveniste, J. (1983)Biochim. Biophys. Acta 751, 298–304.
Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J. (1951)J. Biol. Chem. 193, 265–275.
Cunningham, S.M., Smith, M.J.H., Ford-Hutchinson, A.W., and Walker, J.R. (1979)J. Pathol. 128, 15–20.
Gomez-Cambronero, J., Velasco, S., Mato, J.M., and Sanchez-Crespo, M. (1985)Biochim. Biophys. Acta 845, 516–519.
Lenihan, T.J., and Lee, T.-c. (1984)Biochem. Biophys. Res. Commun. 120, 834–839.
Knack, I., and Röhm, K.-H. (1981)Z. Physiol. Chem. 362, 1119–1130.
Ninio, E., Joly, F., and Bessou, G. (1988)Biochim. Biophys. Acta 963, 288–294.
Ninio, E., Mencia-Huerta, J.M., Heymans, F., and Benveniste, J. (1982)Biochem. Biophys. Acta 710, 23–31.
Nieto, M.L., Velasco, S., and Sanchez Crespo, M. (1988)J. Biol. Chem. 263, 4607–4611.
Wykle, R.L., Malone, B., and Snyder, F. (1980)J. Biol. Chem. 255, 10256–10260.
Lee, T.-c. (1985)J. Biol. Chem. 260, 10952–10955.
Author information
Authors and Affiliations
About this article
Cite this article
Schindler, P.W., Ninio, E. Kinetic studies of human and rat neutrophil lysoPAF acetyltransferase using lysoPAF and dansyllysoPAF as substrates. Lipids 26, 1004–1010 (1991). https://doi.org/10.1007/BF02536492
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02536492